Rosen Law Firm has initiated a securities class action lawsuit against uniQure N.V. (NASDAQ: QURE), alleging that company executives made materially misleading statements regarding the regulatory status of a pivotal study design and the timeline for a Biologics License Application submission to the FDA. The litigation targets purchases made between September 24, 2025, and October 31, 2025, and claims defendants failed to adequately disclose risks of delays to the company's regulatory pathway.
Investors who purchased uniQure shares during the specified period and believe they sustained losses as a result of the alleged misrepresentations are eligible to participate in the action. Legal counsel has emphasized the importance of timely notification, as investors seeking to serve as lead plaintiff in the case must file a declaration by April 13, 2026. Lead plaintiff designation provides shareholders the ability to direct the litigation and potentially recover damages through settlement or judgment.
The case underscores ongoing scrutiny surrounding corporate disclosure practices in the biotechnology sector, where regulatory milestones and approval timelines significantly impact investor valuations. Shareholders with questions about their eligibility or rights in connection with the class action are advised to consult with qualified legal representatives before the deadline.